Raynaud phenomenon and the vascular disease in scleroderma.

PubWeight™: 1.02‹?› | Rank: Top 15%

🔗 View Article (PMID 15577610)

Published in Curr Opin Rheumatol on November 01, 2004

Authors

M Bashar Kahaleh1

Author Affiliations

1: Division of Rheumatology, Department of Medicine, Medical College of Ohio, 1321 Glendale Avenue, Toledo, OH 43617, USA. bkahaleh@mco.edu

Articles citing this

Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest (2007) 5.19

Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol (2010) 1.64

Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum (2013) 0.98

Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management. Int J Clin Rheumtol (2015) 0.95

Macrophage migration inhibitory factor may contribute to vasculopathy in systemic sclerosis. Clin Rheumatol (2008) 0.83

Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with systemic lupus erythematosus and Behçets disease. J Clin Immunol (2012) 0.82

Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis. Ann Rheum Dis (2007) 0.82

Fox-2 protein regulates the alternative splicing of scleroderma-associated lysyl hydroxylase 2 messenger RNA. Arthritis Rheum (2010) 0.80

Methods for the morphological and functional evaluation of microvascular damage in systemic sclerosis. Korean J Intern Med (2014) 0.80

Current perspectives on the immunopathogenesis of systemic sclerosis. Immunotargets Ther (2016) 0.79

Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis. Ann Rheum Dis (2015) 0.75

Cytokines in the immunopathology of systemic sclerosis. Semin Immunopathol (2015) 0.75

Cold hands--strained heart? Advances in the management of Raynaud's phenomenon and pulmonary hypertension. Arthritis Res Ther (2005) 0.75

Targeting Hypoxia Inducible Factors-1α As a Novel Therapy in Fibrosis. Front Pharmacol (2017) 0.75